Atlas Trials

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

Clinical trial NCT02105701 · COMPLETED

Trial details

NCT number
NCT02105701
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis C Infection
Start date
2014-06-05
Primary completion
2015-03-24
Enrollment
420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.